AnalystsAdam WalshAdam Walsh's Stock Forecasts
AnalystsAdam Walsh
Sectors:
Industries:
Analyst Ranking
Top 33%
#1613 out of 4872 analysts
Average Return
+14.39%
Win Rate
63%5 out of 8
Risk vs Reward
Poor
Good
Adam Walsh's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Ascendis Pharma AASND | +58.48% | $70.69 | $112.03 | 2018-08-29 - 2019-08-30 | Strong Buy |
Galapagos NvGLPG | +39.87% | $92.18 | $128.93 | 2018-06-28 - 2019-06-28 | Strong Buy |
Galapagos NvGLPG | +33.71% | $119.71 | $160.07 | 2018-09-11 - 2019-09-12 | Strong Buy |
Ultragenyx Pharmaceutical IncRARE | +17.34% | $54.91 | $64.43 | 2018-04-17 - 2019-04-18 | Strong Buy |
Corcept Therapeutics IncCORT | +10.98% | $16.67 | $18.50 | 2017-08-30 - 2018-05-31 | Strong Buy |
Adam Walsh Analyst Color
Get additional color on Adam Walsh's coverage of popular stocks
Adam Walsh's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Ascendis Pharma AASND | 2 | Strong Buy | $171.00 | N/A | Maintains | 5 years ago |
Reata Pharmaceuticals IncRETA | 2 | Strong Buy | $315.00 | N/A | Maintains | 5 years ago |
Galapagos NvGLPG | 2 | Strong Buy | $111.00 | N/A | Maintains | 7 years ago |
Corcept Therapeutics IncCORT | 2 | Hold | N/A | N/A | Downgrades | 7 years ago |
Ultragenyx Pharmaceutical IncRARE | 1 | Strong Buy | $77.00 | N/A | Maintains | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.